Novartis AG
Change company Symbol lookup
Select an option...
NVS Novartis AG
UNM Unum Group
LLY Eli Lilly and Co
BDC Belden Inc
TTM Tata Motors Ltd
HOG Harley-Davidson Inc
SKY Skyline Champion Corp
MPX Marine Products Corp

Health Care : Pharmaceuticals | Large Cap Value
Based in Switzerland
Company profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Day's Change
-2.26 (-2.79%)
B/A Size
Day's High
Day's Low
(Heavy Day)

Today's volume of 547,855 shares is on pace to be much greater than NVS's 10-day average volume of 1,640,966 shares.


Abbott's stock jumps 9% following authorization of its rapid $5 COVID-19 test

8:38 am ET August 27, 2020 (MarketWatch)

Shares of Abbott Laboratories (ABT) gained 9.1% in premarket trading on Thursday, the day after the company had announced regulatory authorization for a new COVID-19 test that costs $5, does not require instrumentation, and can produce a result in 15 minutes. The test is of particular interest given that there are wait times of days or sometimes weeks ( to receive a COVID-19 test result. Abbott said the test must be performed by a health care professional in a point-of-care setting; however, people who receive the test can download a new free mobile app that will provide a verifiable test result that includes the date the test was performed. Abbott said the display of results is similar to a digital boarding pass used by airlines. "Just as interest in COVID-19 testing seemed to be waning, Abbott once again answers, the bell" Raymond James' Jayson Bedford told investors on Thursday. "The timing of this [emergency use authorization] is a positive surprise, as is the price, accuracy, and capacity." The diagnostics maker has developed and launched six COVID-19 diagnostic and antibody tests during the pandemic. Its stock is up 18.8% year-to-date, while the S&P 500 has gained 7.6%.

-Jaimy Lee; 415-439-6400;

(END) Dow Jones Newswires

August 27, 2020 08:38 ET (12:38 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.